NSEPress Release1d ago · 17 Nov 2026, 07:35 pm
Press Release
Glenmark Pharmaceuticals Limited · GLENMARK
✦ AI Summary▲ PositiveExpansion
Glenmark Pharmaceuticals' subsidiary Ichnos Glenmark Innovation (IGI) submits IND application to US FDA for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk5/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 17, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors".
Attachments (1)
📄pdf
Download →
GLENMARK_17112026193210_SE_Press_Release_17112026.pdf
View document text
November 17, 2026
To, To,
National Stock Exchange of India Limited, BSE Limited,
“Exchange Plaza”, Corporate Relationship Department,
5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring,
Bandra- Kurla Complex, Bandra (East), P.J. Towers, Dalal Street,
Mumbai – 400 051 Mumbai – 400 001
Scrip Name: GLENMARK Scrip Code: 532296
ISIN: INE935A01035 ISIN: INE935A01035
Our Reference No. 72/26-27 Our Reference No. 72/26-27
Dear Sir/ Madam,
Sub: Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a
First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors
Ichnos Glenmark Innovation, Inc. (IGI), today announced the submission of an Investigational New
Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301, a First-in-Class
Multispecific Immune Cell Activator Targeting Solid Tumors.
ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer
(NK) cells.
IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027.
Kindly find attached media release which is self- explanatory.
Request you to take the same on record.
Thanking you.
For Glenmark Pharmaceuticals Limited
Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839
Encl: As above
Glenmark Pharmaceuticals Limited
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com
Ichnos Glenmark Innovation (IGI) Announces IND
Submission to U.S. FDA for ISB 2301, a First-in-Class
Multispecific Immune Cell Activator Targeting Solid
Tumors
ISB 2301 targets three tumor-associated antigens (TAAs) and engages both
T cells and natural killer (NK) cells
IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid
tumors in 2027
NEW YORK, NY, November 17, 2026: Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-
stage biotechnology company focused on developing Multispecific™ therapeutics in oncology,
today announced the submission of an Investigational New Drug (IND) application to the U.S.
Food and Drug Administration (FDA) for ISB 2301.
ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target
three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific
molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and
NK-cell activation. By combining tumor-cell recognition with complementary immune activity,
ISB 2301 is being developed to address biological heterogeneity and immune-suppressive
features of solid tumors.
"Submission of the IND for ISB 2301 marks an important milestone in advancing IGI’s multispecific
oncology pipeline into clinical development,” said Lida Pacaud, M.D., President and Chief
Executive Officer, IGI. “This pentaspecific candidate is designed to integrate multiple tumor-
targeting and immune-engaging functions within a single molecule. Our preclinical results have
demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly
differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in
patients with solid tumors in 2027.”
ISB 2301 was engineered using IGI’s proprietary BEAT® Multispecific Platform and is designed to
recognize three tumor-associated antigens while engaging both T cells and NK cells through
complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC),
checkpoint inhibition, and the induction of a sustained type 1 immune response.
In preclinical studies, ISB 2301 demonstrated favorable pharmacokinetic and tolerability profiles
in non-human primates, supporting the planned evaluation of its safety, tolerability,
pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced solid
tumors.
About IGI
IGI is a global, fully integrated clinical-stage biotechnology company focused on developing
innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust
pipeline of novel, first-in-class Multispecifics™ powered by its proprietary BEAT® technology
platform. The platform has demonstrated clinical proof of concept through ISB 2001, an
investigational CD38 × BCMA × CD3 trispecific T-cell engager that has shown promising anti-
tumor activity and favorable safety profile in patients with heavily pretreated relapsed/refractory
multiple myeloma in an investigational Phase 1 study. IGI is committed to delivering
breakthrough curative therapies to improve and extend the lives of patients battling
hematological malignancies and solid tumors. For more information, visit www.IGInnovate.com.
IGI Corporate Communications:
Corporate.communications@IGInnovate.com